The Efficacy and Safety of Sirolimus for Plastic Bronchitis:a Pilot Study
试验速览
- 阶段
- 2 期
- 入组人数
- 10
- 试验地点
- 1
- 主要终点
- changes of coughing score
研究概览
简要总结
There is no confirmed drug therapy for plastic bronchitis. The study wish to test the effectiveness and safety of sirolimus (rapamycin) in patients with lymphatic plastic bronchitis.
详细描述
Plastic bronchitis is a rare respiratory disorder characterized by formation of gelatinous or rigid cast of bronchial tree. Confirmed drug therapy for plastic bronchitis is lacking. Recently, part of plastic bronchitis has been found to have dysfunction of lymphatic circulation in the lung. Pulmonary lymphatic perfusion syndrome (PLPS) is regarded as a major mechanism of lymphatic plastic bronchitis. Sirolimus (rapamycin) has not been studied in plastic bronchitis, however, it has been shown effective in several lymphatic disorders, such as lymphangioleiomyomatosis, generalized lymphatic anomaly (GLA) including lymphangiomatosis, etc. We wish to test the effectiveness of sirolimus in lymphatic plastic bronchitis.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 13 Years 至 —(Child, Adult, Older Adult)
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •plastic bronchitis
- •pulmonary lymphatic perfusion syndrome demonstrated on 68Ga-NEB positron emission tomography (PET)
排除标准
- •Pregnancy and breastfeeding
- •Severe cardiovascular, hepatic and renal dysfunction
- •allergy to sirolimus or 68Ga-NEB
研究组 & 干预措施
Sirolimus
Patients in sirolimus group will receive sirolimus for 6 months.
干预措施: Sirolimus (Drug)
结局指标
主要结局
changes of coughing score
时间窗: 6 months
measured by coughing VAS score (0-10) at baseline, 3 months and the end of study
changes of pulmonary lymphatic perfusion distribution
时间窗: 6 months
quantitatively measured with 68Ga-NEB positron emission tomography (PET) at baseline and the end of study
次要结局
- changes of breathlessness score(6 months)
- Number of participants with treatment-related adverse events as assessed by CTCAE v4.0(6 months)
- change of health-related quality of life(6 months)
- changes of pulmonary function (FEV1, FVC)(6 months)
- changes of six minutes walking distance(6 months)
